Bronchial Thermoplasty in Severe Persistent Asthma
What is the purpose of this trial?
As Conditions of Approval of the PMA for the Alair System, the FDA requires Asthmatx to generate data to assess the durability of the BT treatment effect as well as safety data in the intended use population in the United States.
- 18 Years - 65 Years
- Asthmatx, Inc.
Boston Scientific Corporation
- April 2011
- Last Updated:
- January 15, 2013
- Study HIC#:
Clinicaltrials.gov ID: NCT01350336